Key facts
- Notable investors include Aditum Bio, Mabwell.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Kalexo Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Kalexo Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kalexo Bio
Developer of therapies intended for patients in areas of high unmet need. The company offers the development and commercialization of small interfering ribonucleic acid therapies, enabling patients with elevated cholesterol or dyslipidemia to prevent cardiovascular diseases and have easy access to the drugs required to manage their condition.
- Sector
- Healthcare
- HQ
- Oakland, CA, United States
- Founded
- 2023
- Ownership
- Privately Held (backing)
Kalexo Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kalexo Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kalexo Bio in its N-PORT filings yet. We sweep new filings monthly.